Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: February 29, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PIPERACILLIN AND TAZOBACTAM

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Piperacillin And Tazobactam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003805 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1997-11-01 RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00044746 Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2000-10-01 Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.
NCT00044759 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 1969-12-31 To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00167999 Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2005-02-01 To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Piperacillin And Tazobactam

Condition Name

Condition Name for Piperacillin And Tazobactam
Intervention Trials
Infection 4
Perforated Appendicitis 3
Bacteremia 3
Appendicitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Piperacillin And Tazobactam
Intervention Trials
Infection 21
Communicable Diseases 14
Pneumonia 9
Appendicitis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Piperacillin And Tazobactam

Trials by Country

Trials by Country for Piperacillin And Tazobactam
Location Trials
United States 95
Germany 15
Italy 13
Canada 12
China 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Piperacillin And Tazobactam
Location Trials
Texas 6
Florida 6
New York 5
California 5
New Jersey 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Piperacillin And Tazobactam

Clinical Trial Phase

Clinical Trial Phase for Piperacillin And Tazobactam
Clinical Trial Phase Trials
Phase 4 25
Phase 3 19
Phase 2/Phase 3 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Piperacillin And Tazobactam
Clinical Trial Phase Trials
Completed 29
Recruiting 18
Not yet recruiting 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Piperacillin And Tazobactam

Sponsor Name

Sponsor Name for Piperacillin And Tazobactam
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 8
Merck Sharp & Dohme Corp. 8
M.D. Anderson Cancer Center 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Piperacillin And Tazobactam
Sponsor Trials
Other 97
Industry 32
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
Medtronic
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.